Triggering Intracellular Receptors for Vaccine Adjuvantation

Trends in Immunology

Volumn 37, Issue 9, 2016, Pages 573-587

  Gutjahr, Alice ^a,b,c   Tiraby, Gérard ^b   Perouzel, Eric ^b   Verrier, Bernard ^a   Paul, Stéphane ^c  

^a UNIVERSITÉ LYON 1   (France)

^b Zone industrielle de Montaudran   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; CELL RECEPTOR; DNA; LIGAND; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PATTERN RECOGNITION RECEPTOR; RIG I LIKE RECEPTOR; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; VACCINE; IMMUNOLOGICAL ADJUVANT;

CYTOSOL; DRUG EFFICACY; ENDOSOME; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; NONHUMAN; REVIEW; ANIMAL; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; MOLECULARLY TARGETED THERAPY; SECOND MESSENGER; SIGNAL TRANSDUCTION; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ENDOSOMES; HUMANS; IMMUNITY, INNATE; MOLECULAR TARGETED THERAPY; SECOND MESSENGER SYSTEMS; SIGNAL TRANSDUCTION; VACCINATION; VACCINES;

EID: 84992497238     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2016.07.001     Document Type: Review

References (104)

1. 1 Minor, P.D., Live attenuated vaccines: historical successes and current challenges. Virology 479/480 (2015), 379–392.
2. 2 Sasaki, S., et al. Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. J. Clin. Invest. 121 (2011), 3109–3119.
3. 3 Camilloni, B., et al. Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: a literature review. Hum. Vaccin. Immunother. 11 (2015), 553–563.
4. fh cells and promote germinal center induction. Proc. Natl. Acad. Sci. 109 (2012), 1080–1085.
5. 5 Yam, K.K., et al. AS03-adjuvanted, very-low-dose influenza vaccines induce distinctive immune responses compared to unadjuvanted high-dose vaccines in BALB/c mice. Front. Immunol. 6 (2015), 1–13.
6. 6 Pattani, A., et al. Microneedle mediated intradermal delivery of adjuvanted recombinant HIV-1 CN54gp140 effectively primes mucosal boost inoculations. J. Control. Release 162 (2012), 529–537.
7. 7 Nochi, T., et al. Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nat. Mater. 9 (2010), 572–578.
8. 8 Park, H., et al. Polyinosinic-polycytidylic acid is the most effective TLR adjuvant for SIV Gag protein-induced T cell responses in nonhuman primates. J. Immunol. 190 (2013), 4103–4115.
9. 9 Iwasaki, A., Medzhitov, R., Control of adaptive immunity by the innate immune system. Nat. Immunol. 16 (2015), 343–353.
10. 10 Alexopoulou, L., et al. Recognition of double-stranded RNA and activation of NF-kappa B by Toll-like receptor 3. Nature 413 (2001), 732–738.
11. + Th1 immunity with poly IC as adjuvant. J. Exp. Med. 206 (2009), 1589–1602.
12. + T cell immunity together with a dendritic cell targeted vaccine. Proc. Natl. Acad. Sci. U.S.A. 105 (2008), 2574–2579.
13. 13 Ichinohe, T., et al. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J. Virol. 79 (2004), 2910–2919.
14. 14 Mitchell, W.M., et al. Discordant biological and toxicological species responses to TLR3 activation. Am. J. Pathol. 184 (2014), 1062–1072.
15. 15 Matsumoto, M., et al. Defined TLR3-specific adjuvant that induces NK and CTL activation without significant cytokine production in vivo. Nat. Commun., 6, 2015, 6280.
16. 16 Thompson, E.A., et al. Human anti-CD40 antibody and poly IC:LC adjuvant combination induces potent T cell responses in the lung of nonhuman primates. J. Immunol. 195 (2015), 1015–1024.
17. 17 Jurk, M., et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat. Immunol., 3, 2002, 499.
18. 18 Hung, I.F.N., et al. Immunogenicity of intradermal trivalent influenza vaccine with topical imiquimod: a double blind randomized controlled trial. Clin. Infect. Dis. 59 (2014), 1246–1255.
19. 19 Zhang, W.W., Matlashewski, G., Immunization with a Toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice. Infect. Immun. 76 (2008), 3777–3783.
20. 20 Lynn, G.M., et al. In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity. Nat. Biotechnol. 33 (2015), 1201–1210.
21. 21 Eng, N.F., et al. The potential of 1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV™ review. Hum. Vaccines Immunother. 9 (2013), 1661–1672.
22. 22 Schellack, C., et al. IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine 24 (2006), 5461–5472.
23. 23 Chu, C-Y., et al. Development of a subunit vaccine containing recombinant Riemerella anatipestifer outer membrane protein A and CpG ODN adjuvant. Vaccine 33 (2014), 92–99.
24. 24 Zhou, Y., et al. Combinations of various CpG motifs cloned into plasmid backbone modulate and enhance protective immunity of viral replicon DNA anthrax vaccines. Med. Microbiol. Immunol. 204 (2015), 481–491.
25. 25 Rigby, R.E., et al. RNA:DNA hybrids are a novel molecular pattern sensed by TLR 9. EMBO J. 33 (2014), 542–558.
26. 26 Franchi, L., et al. Function of Nod-like receptors in microbial recognition and host defense. Immunol. Rev. 227 (2009), 106–128.
27. 27 Kanneganti, T-D., Central roles of NLRs and inflammasomes in viral infection. Nat. Rev. Immunol. 10 (2010), 688–698.
28. 28 Chamaillard, M., et al. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat. Immunol. 4 (2003), 702–707.
29. 29 Girardin, S.E., et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem. 278 (2003), 8869–8872.
30. 30 Pavot, V., et al. Encapsulation of Nod1 and Nod2 receptor ligands into poly(lactic acid) nanoparticles potentiates their immune properties. J. Control. Release 167 (2013), 60–67.
31. 31 Wischke, C., et al. Potential of NOD receptor ligands as immunomodulators in particulate vaccine carriers. J. Control. Release 164 (2012), 299–306.
32. 32 Pavot, V., et al. Directing vaccine immune responses to mucosa by nanosized particulate carriers encapsulating NOD ligands. Biomaterials 75 (2016), 327–339.
33. 33 Jackson, E.M., Herbst-Kralovetz, M.M., Intranasal vaccination with murabutide enhances humoral and mucosal immune responses to a virus-like particle vaccine. PLoS ONE, 7, 2012, e41529.
34. 34 Kim, D., et al. Nod2-mediated recognition of the microbiota is critical for mucosal adjuvant activity of cholera toxin. Nat. Med. 22 (2016), 524–530.
35. 35 Loo, Y-M., Gale, M. Jr., Immune signaling by RIG-I-like receptors. Immunity 34 (2012), 680–692.
36. 36 Yoneyama, M., et al. Shared and unique functions of the DExD/H-Box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J. Immunol. 175 (2005), 2851–2858.
37. 37 Kawai, T., et al. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat. Immunol. 6 (2005), 981–988.
38. 38 Kato, H., et al. Cell type-specific involvement of RIG-I in antiviral response. Immunity 23 (2005), 19–28.
39. 39 Beljanski, V., et al. Enhanced influenza virus-Like particle vaccination with a structurally optimized RIG-I agonist as adjuvant. J. Virol. 89 (2015), 10612–10624.
40. 40 Kulkarni, R.R., et al. Activation of the RIG-I pathway during influenza vaccination enhances the germinal center reaction, promotes T follicular helper cell induction, and provides a dose-sparing effect and protective immunity. J. Virol. 88 (2014), 13990–14001.
41. 41 Martínez-Gil, L., et al. A Sendai virus-derived RNA agonist of RIG-I as a virus vaccine adjuvant. J. Virol. 87 (2013), 1290–1300.
42. 42 Hochheiser, K., et al. Cutting edge: the RIG-I ligand 3pRNA potently improves CTL cross-priming and facilitates antiviral vaccination. J. Immunol. 196 (2016), 2439–2443.
43. 43 Duewell, P., et al. Targeted activation of melanoma differentiation-associated protein 5 (MDA5) for immunotherapy of pancreatic carcinoma. Oncoimmunology, 2015, 1–12 e1029698.
44. 44 Liniger, M., et al. MDA5 can be exploited as efficacious genetic adjuvant for DNA vaccination against lethal H5N1 influenza virus infection in chickens. PLoS ONE 7 (2012), 1–9.
45. 45 Ishikawa, H., Barber, G.N., STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 455 (2008), 674–678.
46. 46 Sun, L., et al. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type-I interferon pathway. Science 339 (2013), 786–791.
47. 47 Wu, J., et al. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science 826 (2014), 826–831.
48. 48 Gao, D., et al. Cyclic GMP-AMP synthase is an innate immune sensor of HIV and other retroviruses. Science 341 (2013), 903–906.
49. 49 Schoggins, J.W., et al. Pan-viral specificity of IFN-induced genes reveals newroles for cGAS in innate immunity. Nat. Lett. 505 (2014), 691–695.
50. 50 Collins, A.C., et al. Cyclic GMP-AMP synthase is an innate immune DNA sensor for Mycobacterium tuberculosis. Cell Host Microbe 17 (2015), 820–828.
51. 51 Dey, B., et al. A bacterial cyclic dinucleotide activates the cytosolic surveillance pathway and mediates innate resistance to tuberculosis. Nat. Med. 21 (2015), 1–8.
52. 52 Mankan, A.K., et al. Cytosolic RNA:DNA hybrids activate the cGAS–STING axis. EMBO J. 33 (2014), 2937–2946.
53. 53 Li, X-D., et al. Pivotal roles of cGAS-cGAMP signaling in antiviral defense and immune adjuvant effects. Science 120 (2013), 1390–1395.
54. 54 Škrnjug, I., et al. Cyclic GMP-AMP displays mucosal adjuvant activity in mice. PLoS One 9 (2014), 1–7.
55. 55 Parvatiyar, K., et al. The helicase DDX41 recognizes the bacterial secondary messengers cyclic di-GMP and cyclic di-AMP to activate a type I interferon immune response. Nat. Immunol. 13 (2012), 1155–1161.
56. 56 Blaauboer, S.M., et al. The mucosal adjuvant cyclic di-GMP enhances antigen uptake and selectively activates pinocytosis-efficient cells in vivo. Elife 4 (2015), 1–25.
57. 57 Hanson, M.C., et al. Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants. J. Clin. Invest. 125 (2015), 2532–2546.
58. 58 Alyaqoub, F.S., et al. In vivo synthesis of cyclic-di-GMP using a recombinant adenovirus preferentially improves adaptive immune responses against extracellular antigens. J. Immunol. 196 (2016), 1741–1752.
59. 59 Woo, S-R., et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41 (2014), 830–842.
60. 60 Chandra, D., et al. STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer. Cancer Immunol. Res. 2 (2014), 901–910.
61. 61 Miyabe, H., et al. A new adjuvant delivery system ‘cyclic di-GMP/YSK05 liposome’ for cancer immunotherapy. J. Control. Release 184 (2014), 20–27.
62. 62 Fu, J., et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci. Transl. Med. 7 (2015), 1–24.
63. 63 Li, T., et al. Antitumor activity of cGAMP via stimulation of cGAS-cGAMP-STING-IRF3 mediated innate immune response. Sci. Rep., 6, 2016, 19049.
64. 64 Carroll, E.C., et al. The vaccine adjuvant chitosan promotes cellular immunity via DNA sensor cGAS-STING-dependent induction of type I interferons. Immunity 44 (2016), 597–608.
65. 65 Netea, M.G., et al. Nucleotide-binding oligomerization domain-2 modulates specific TLR pathways for the induction of cytokine release. J. Immunol. 174 (2005), 6518–6523.
66. 66 Fritz, J.H., et al. Synergistic stimulation of human monocytes and dendritic cells by Toll-like receptor 4 and NOD1- and NOD2-activating agonists. Eur. J. Immunol. 35 (2005), 2459–2470.
67. 67 Khan, N., et al. Signaling through NOD-2 and TLR-4 bolsters the T cell priming capability of dendritic cells by inducing autophagy. Sci. Rep., 6, 2016, 19084.
68. 68 Schwarz, H., et al. TLR8 and NOD signaling synergistically induce the production of IL-1β and IL-23 in monocyte-derived DCs and enhance the expression of the feedback inhibitor SOCS2. Immunobiology 218 (2013), 533–542.
69. 69 Pavot, V., et al. Cutting edge: new chimeric NOD2/TLR2 adjuvant drastically increases vaccine immunogenicity. J. Immunol. 193 (2014), 5781–5785.
70. 70 Goff, P.H., et al. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses. J. Virol. 89 (2015), 3221–3235.
71. 71 Wenink, M.H., et al. TLR2 promotes Th2/Th17 responses via TLR4 and TLR7/8 by abrogating the type I IFN amplification loop. J. Immunol. 183 (2009), 6960–6970.
72. 72 Hu, Y., et al. Synergy of TLR3 and 7 ligands significantly enhances function of DCs to present inactivated PRRSV antigen through TRIF/MyD88–NF-κB signaling pathway. Sci. Rep., 6, 2016, 23977.
73. 73 Arsenault, R.J., et al. Combined CpG and poly I:C stimulation of monocytes results in unique signaling activation not observed with the individual ligands. Cell. Signal. 25 (2013), 2246–2254.
74. 74 Le Noci, V., et al. Poly(I:C) and CpG-ODN combined aerosolization to treat lung metastases and counter the immunosuppressive microenvironment. Oncoimmunology 4 (2015), 1–10.
75. 75 Temizoz, B., et al. TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN. Eur. J. Immunol. 45 (2015), 1159–1169.
76. 76 Kool, M., et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J. Exp. Med. 205 (2008), 869–882.
77. 77 Bentala, H., et al. Removal of phosphate from lipid A as a strategy to detoxify lipopolysaccharide. Shock 18 (2002), 561–566.
78. 78 Dupont, J., et al. A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine. Vaccine 24 (2006), 7167–7174.
79. 79 Clark, T.W., et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N. Engl. J. Med. 361 (2009), 2424–2435.
80. 80 Leroux-Roels, I., et al. Priming with AS03A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine 28 (2010), 849–857.
81. 81 Van Herck, K., et al. Long-term antibody persistence in children after vaccination with the pediatric formulation of an aluminum-free virosomal hepatitis a vaccine. Pediatr. Infect. Dis. J. 34 (2015), e85–e91.
82. 82 Morrison, C., Landmark green light for Mosquirix malaria vaccine. Nat. Biotechnol. 33 (2015), 1015–1016.
83. 83 RTSS Clinical Trials Partnership, Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 6736 (2015), 31–45.
84. 84 Koofhethile, C.K., et al. CD8+ T cell breadth and ex vivo virus inhibition capacity distinguish between viremic controllers with and without protective HLA class I alleles. J. Virol. 90 (2016), 6818–6831.
85. + T cells. PLoS ONE 10 (2015), 1–18.
86. 86 Soriano, A., The paradigm of ASIA (autoimmune/Inflammatory syndrome induced by adjuvants): a concept in evolution. Isr. Med. Assoc. J. 16 (2014), 113–114.
87. 87 Li, Y., et al. Efficient cross-presentation depends on autophagy in tumor cells. Cancer Res. 68 (2008), 6889–6895.
88. 88 Chen, M., et al. Essential role for autophagy in the maintenance of immunological memory against influenza infection. Nat. Med. 20 (2014), 503–510.
89. 89 Jagannath, C., et al. Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells. Nat. Med. 15 (2009), 267–276.
90. 90 Delgado, M.A., et al. Toll-like receptors control autophagy. Embo J. 27 (2008), 1110–1121.
91. 91 Travassos, L.H., et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat. Immunol. 11 (2010), 55–62.
92. 92 Watson, R.O., et al. The cytosolic sensor cGAS detects Mycobacterium tuberculosis DNA to induce type I interferons and activate autophagy. Cell Host Microbe 17 (2015), 811–819.
93. 93 Saiga, H., et al. The recombinant BCG ΔureC::hly vaccine targets the AIM2 inflammasome to induce autophagy and inflammation. J. Infect. Dis. 211 (2015), 1831–1841.
94. 94 Cheng, J.Y., Kananathan, R., CIMAvax EGF vaccine for stage IIIb/IV non-small cell lung carcinoma. Hum. Vaccines Immunother. 8 (2012), 1799–1801.
95. 95 Laurens, M.B., et al. Extended safety, immunogenicity and efficacy of a blood-stage malaria vaccine in Malian children: 24-month follow-up of a randomized, double-blinded phase 2 trial. PLoS ONE 8 (2013), 1–9.
96. 96 Kruit, W.H.J., et al. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J. Clin. Oncol. 31 (2013), 2413–2420.
97. 97 van Dissel, J.T., et al. A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human. Vaccine 32 (2014), 7098–7107.
98. 98 Turley, C.B., et al. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 29 (2011), 5145–5152.
99. 99 Coler, R.N., et al. From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3 + GLA-SE. Clin. Transl. Immunol., 4, 2015, e35.
100. 3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial. PLoS ONE 9 (2014), 1–19.
101. 101 Yoshitake, Y., et al. Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS. Clin. Cancer Res. 21 (2015), 312–321.
102. 102 Chung, K.Y., et al. ISCOMATRIX™ adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with virus neutralization in humans. Vaccine 33 (2015), 3953–3962.
103. + T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with α-type 1 polarized dendritic cells and polyinosinic–polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J. Clin. Oncol. 29 (2011), 330–336.
104. 104 Waite, D.C., et al. Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21. Vaccine 19 (2001), 3957–3967.